Related Experiment Video

Updated: May 21, 2026

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

Targeting the B-cell lymphoma/leukemia 2 family in cancer

Matthew S Davids1, Anthony Letai

  • 1Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|June 1, 2012
PubMed

Insights

The B-cell lymphoma/leukemia 2 (BCL-2) protein family regulates programmed cell death. Understanding BCL-2 offers new cancer therapies and biomarkers for improved patient treatment.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Biochemistry

Background:

  • The B-cell lymphoma/leukemia 2 (BCL-2) protein family plays a crucial role in regulating apoptosis.
  • Over 25 years of research have significantly advanced our understanding of BCL-2's function in programmed cell death.
  • Dysregulation of BCL-2 family proteins is implicated in various cancers.

Purpose of the Study:

  • To review the current understanding of the BCL-2 protein family's role in apoptosis and cancer.
  • To highlight the clinical development of drugs targeting BCL-2 and related proteins.
  • To discuss the implications of BCL-2 research for cancer therapy and biomarker discovery.

Main Methods:

  • Literature review of studies on the BCL-2 protein family.
  • Analysis of clinical trial data for BCL-2 inhibitors.
  • Synthesis of information on the relationship between BCL-2, chemotherapy, and cancer chemosensitivity.

Main Results:

  • The BCL-2 family critically controls cell death pathways.
  • Clinical trials show promise for BCL-2 inhibitors, especially in lymphoid malignancies.
  • BCL-2 family insights explain chemotherapy efficacy and cancer chemosensitivity variations.

Conclusions:

  • Targeting the BCL-2 family offers a promising therapeutic strategy for cancer treatment.
  • Further research into the BCL-2 family can yield improved predictive biomarkers for oncologists.
  • Exploiting BCL-2 biology holds potential for developing more effective cancer therapies.

More Related Videos

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...